EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring

Yuji Kawaguchi iD, Yuriko Hajika, Maho Rinka, Koji Masumoto, Jun Sawa, Kenji Hamazaki, Yasuro Kumeda

Journal of Diabetes Investigation · 2024-05 · 15 (5) · 598-607

DOI: 10.1111/jdi.14151 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 23.01.2024. Verfasst von Yuji Kawaguchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin Glargine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim/Introduction Insulin glargine U100/lixisenatide and insulin degludec/liraglutide are fixed‐ratio combinations containing basal insulin and a glucagon‐like peptide‐1 receptor agonist capable of reducing both fasting and postprandial blood glucose levels with a single formulation. This study aimed to compare the time in range (TIR) and the time below range (TBR) level 1 using professional continuous glucose monitoring and to establish criteria for the differential use of the fixed‐ratio combinations. Materials and Methods Thirty‐six outpatients with type 2 diabetes mellitus (24 men and 12 women; average age, 62.1 years) were randomly assigned to the groups. At 0 and 18 weeks, a device was worn to compare the TIR and TBR level 1. The correlation between the C‐peptide index at baseline and TIR at 18 weeks was assessed.

Results

The TIR and TBR level 1 showed no significant differences between the two groups. Both groups showed significant positive correlations between the C‐peptide index and the TIR ( P = 0.002, r = 0.679; P = 0.002, r = 0.681, respectively). The changes in glycemic variability, therapeutic indices, and body mass index were not significantly different among the groups ( P > 0.05). The receiver operating curve analysis revealed that the cut‐off values of the C‐peptide index to achieve TIR of >70% at 18 weeks were 1.258 (sensitivity, 77.8%; specificity, 100%) and 1.099 (sensitivity, 57.1%; specificity, 90.9%) in the insulin glargine U100/lixisenatide and insulin degludec/liraglutide groups, respectively.

Conclusions

A TIR of >70% was achieved for both fixed‐ratio combinations without significant differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 2Hypoglycemic AgentsInsulin GlargineInsulin, Long-ActingLiraglutideAgedFemaleHumansMaleMiddle AgedContinuous Glucose MonitoringDrug CombinationsPeptidesTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 Receptor

Stichwörter der Autor:innen

C‐peptide indexIDegLiraIGlarLixi

Substanzen

Blood GlucoseDrug CombinationsHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingLiraglutidePeptidesGlucagon-Like Peptide-1 Receptor Agonistsinsulin degludeclixisenatide

Autor:innen und Institutionen

  • Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.

ORCID-Profile: Yuji Kawaguchi

Zitieren

APA

Kawaguchi, Y., Hajika, Y., Rinka, M., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2024). Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring. Journal of Diabetes Investigation, 15(5), 598-607. https://doi.org/10.1111/jdi.14151

Vancouver

Kawaguchi Y, Hajika Y, Rinka M, Masumoto K, Sawa J, Hamazaki K, et al. Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring. Journal of Diabetes Investigation. 2024;15(5):598-607. doi:10.1111/jdi.14151

BibTeX
@article{Kawaguchi2024,
  author = {Kawaguchi, Yuji and Hajika, Yuriko and Rinka, Maho and Masumoto, Koji and Sawa, Jun and Hamazaki, Kenji and Kumeda, Yasuro},
  title = {Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U‐100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  volume = {15},
  number = {5},
  pages = {598--607},
  doi = {10.1111/jdi.14151}
}
Kostenlos starten →